|
1. A method of detecting a biomarker in a tumor sample obtained from a patient suffering from or suspected of suffering from a cancer, the method comprising measuring in the tumor sample the nucleic acid expression level of each and every biomarker from a plurality of biomarkers consisting of only Alpha-1-B glycoprotein (A1BG); Acid Phosphatase, Prostate (ACPP); APC2, WNT Signaling Pathway Regulator (APC2); Aquaporin 5 (AQP5); asialoglycoprotein receptor 1 (ASGR1); brevican (BCAN); BCL2 like 15 (BCL2L15); keratinocyte differentiation factor 1 (C1orf172); calcyphosine (CAPS); Cbl proto-oncogene C (CBLC); cadherin 1 (CDH1); carcinoembryonic antigen related cell adhesion molecule 5 (CEACAM5), carcinoembryonic antigen related cell adhesion molecule 6 (CEACAM6); multivesicular body protein 4C (CHMP4C); chloride channel accessory 2 (CLCA2); claudin 4 (CLDN4); collagen type XI alpha 2 chain (COL11A2); crumbs cell polarity complex component 3 (CRB3); cathepsin E (CTSE); cubilin (CUBN); cytochrome P450 family 2 subfamily B member 7, pseudogene (CYP2B7P1); distal-less homeobox 5 (DLX5); dimethylglycine dehydrogenase (DMGDH); E74 like ETS transcription factor 3 (ELF3); empty spiracles homeobox 2 (EMX2); EMX2 opposite strand/antisense RNA (EMX2OS); epithelial cell adhesion molecule (EPCAM); erb-b2 receptor tyrosine kinase 3 (ERBB3); estrogen receptor 1 (ESR1); family with sequence similarity 171 member A2 (FAM171A2); folate hydrolase 1 (FOLH1); gamma-aminobutyric acid type A receptor pi subunit (GABRP); GATA binding protein 3 (GATA3); glucosaminyl (N-acetyl) transferase 3, mucin type (GCNT3); glypican 2 (GPC2); G protein-coupled receptor 35 (GPR35); G protein-coupled receptor class C group 5 member A (GPRC5A); grainyhead like transcription factor 2 (GRHL2); HNF 1 homeobox A (HNF1A); hemopexin (HPX); iodotyrosine deiodinase (IYD); keratin 18 (KRT18); keratin 6A (KRT6A); keratin 6B (KRT6B); keratin 81 (KRT81); keratin 8 (KRT8); ladinin 1 (LAD 1); LCK proto-oncogene, Src family tyrosine kinase (LCK); galectin 4 (LGALS4); LY6/PLAUR domain containing 1 (LYPD1); MARVEL domain containing 3 (MARVELD3); maternally expressed 3 (MEG3); mucin 13, cell surface associated (MUC13); mucin 16, cell surface associated (MUC16); mucin 4, cell surface associated (MUC4); MYCN proto-oncogene, bHLH transcription factor (MYCN); napsin A aspartic peptidase (NAPSA); NK3 homeobox 1 (NKX3-1); natriuretic peptide receptor 1 (NPR1); paired box 8 (PAX8); preferentially expressed antigen in melanoma (PRAME); prostate stem cell antigen (PSCA); nectin cell adhesion molecule 4 (PVRL4); calcium binding protein P (S100P); spalt like transcription factor 4 (SALL4); surfactant protein D (SFTPD); premelanosome protein (SILV); signaling threshold regulating transmembrane adaptor 1 (SIT1); solute carrier family 26 member 4 (SLC26A4); solute carrier family 3 member 1 (SLC3A1); solute carrier family 45 member 3 (SLC45A3); SRY-box 17 (SOX17); SAM pointed domain containing ETS transcription factor (SPDEF); serine peptidase inhibitor, Kunitz type 2 (SPINT2); transcription elongation factor A like 5 (TCEAL5); thyroglobulin (TG); collectrin, amino acid transport regulator (TMEM27); tumor protein p63 (TP63); transcriptional repressor GATA binding 1 (TRPS 1); tetraspanin 8 (TSPAN8); uroplakin 3B (UPK3B); vitronectin (VTN); zinc finger protein 578 (ZNF578); and zinc finger protein 695 (ZNF695) using an amplification, hybridization and/or sequencing assay.
|